What does SE stand for?

Surrogate Endpoint

This definition appears very rarely and is found in the following Acronym Finder categories:

Science, medicine, engineering, etc.

Other Resources:

<< Previous	Abbreviation Database Surfer		Next >>
Superintending Engineer Supplier Exchange Supplies & Equipment Support Element Support Equipment Supportable Evaluation Supported Education Supported Employment Supporting Establishment surface de l'exploitation		Surveillant d'Externat (French: Supervisor of Clerkship) Survivability Enhancement Survival Equipment Suspo-Emulsion Sweden (Internet top-level domain) Swine Erysipelas Switching Element Synchronization Element Synchronous Editing Syntax Element (video coding)

Samples in periodicals archive:

Perceptive is committed to continually incorporating innovative state-of-the-art technologies into our capabilities to help biopharmaceutical companies further improve the use of medical imaging as a surrogate endpoint, or biomarker.

United States : Perceptive Informatics Expands Nuclear Imaging ...

The GAO concluded that the FDA has no policy for pulling drugs off the market that were approved using surrogate endpoints.

GAO: FDA fails to follow up on unproven drugs

The GAO concluded that the FDA has no policy for pulling drugs off the market that were approved using surrogate endpoints.

GAO: FDA fails to follow up on unproven drugs

Zevalin is also indicated, under accelerated approval, for the treatment of relapsed or refractory, rituximab-naive, low-grade and follicular NHL based on studies using a surrogate endpoint of overall response rate.

Cell Therapeutics Exercises Its Option to Sell Interest in Zevalin ...

Even in the case of RF ablation, the surrogate endpoint is of no help if the patient has to go on anti-arrhythmic drugs "in the follow-up period," in which case that patient should be counted as a study failure.

Market Updates: FDA issues trial guidance for atrial flutter ablation

The US Food and Drug Administration (FDA) has based approval on glucose-lowering drugs (eg, sulfonylureas, thiazolidenediones, metformin, insulin) on such surrogate endpoints as capacity to reduce fasting blood sugar and hemoglobin A1c levels.

Raising the bar for diabetes drug approval

The FDA has indicated that reduction of LDL-cholesterol is an acceptable surrogate endpoint for accelerated approval of mipomersen for use in patients with homozygous familial hypercholesterolemia (hoFH).

FDA PROVIDES CLARITY TO ISIS ON MIPOMERSEN REQUIREMENTS

For years, the Food and Drug Administration (FDA) has allowed the use of surrogate endpoints (such as LDL-C reduction) to prove efficacy and clear new drugs.

The cholesterol controversy continues